Editor's Note: Green and red arrows refer to intraday stock price movement.
NEW YORK (
CHANGE IN RATINGS
(ADBE - Get Report)
upgraded at UBS from Neutral to Buy, UBS said. $40 price target. Survey suggests that demand is stabilizing.
(C - Get Report)
downgraded at Goldman to Buy from Neutral, Goldman Sachs said. Company also removed from the Conviction List.
(CAKE - Get Report)
upgraded at Sterne Agee from Neutral to Buy, Sterne Agee said. $36 price target. Valuation call, following the recent pullback.
(CBOE - Get Report)
upgraded at Credit Suisse to Outperform from Neutral. Strong fundamentals and more deals coming, Credit Suisse said. Price target raised to $32 from $25.
rated new Buy at Goldman. $48 price target. Company can deliver consistent cash flow growth.
downgraded at JP Morgan from Neutral to Underweight. $42 price target. Consensus estimates appear too high.
(FITB - Get Report)
upgraded at FBR from Market Perform to Outperform, FBR Capital Markets said. $17 price target. Company has the most relative excess capital.
(FSLR - Get Report)
estimates, target boosted at Goldman. Shares of FSLR now seen reaching $190, according to Goldman Sachs. Estimates also upped, given improved volume visibility. Buy rating.
(FSLR - Get Report)
downgraded at UBS from Buy to Neutral, UBS said. Valuation call, based on a $180 price target.
downgraded at BB&T to Hold, BB&T Capital said. Company guided toward lower near-term margins.
upgraded at Deutsche to Buy, Deutsche Bank said. Company is seeing solid growth an boosted its dividend. $60 price target.
upgraded at Soleil from Accumulate to Buy, Soleil Securities said. Valuation call, based on a $54 price target. Hospital spending appears to be improving.
rated new Hold at Canaccord. $28 price target. Stock is pricing in the potential for increased competition.
rated new Buy at Kaufman. $24 price target. Stock trades at a significant discount to its peers.
downgraded at Deutsche to Hold. $19 price target. Company has limited earnings visibility.
downgraded at Piper to Underweight. $15 price target. Company is seeing lower growth across the board.
downgraded at ThinkEquity from Buy to Hold, ThinkEquity said. $18 price target. Company slashed its forward guidance.
downgraded at Citi from Buy to Hold on disappointing 4Q10 results, Citigroup said. Price target cut to $20 from $26.
downgraded at Baird from Outperform to Neutral. $18 price target. Company lowered its earnings outlook.